BRD4 Targeted Therapies Market Opportunity, Technology Platform, Development Trends & Clinical Trials Insights 2026
BRD4 Targeted Therapies Market Opportunity, Technology Platform, Development Trends & Clinical Trials Insights 2026 Report Findings & Highlights:
BRD4 targeted therapies is one of the most rapidly evolving, most exciting and promising sub field within both epigenetic drug development and precision oncology landscape. As the crucial master transcriptional regulator controlling tumor growth, proliferation, metastasis, immunity, resistance to treatment, the bromodomain containing protein 4 (BRD4) has become an incredibly exciting target in the treatment of multiple cancer types. Different from existing cancer drug targets modulating specific signaling pathways, BRD4 as a transcriptional hub plays a pivotal role to orchestrate tumor’s key oncogenic transcriptional program including MYC driven gene expression and super enhancer function.
The path to the development of BRD4 targeted therapies has evolved from first generation pan BET inhibitors to increasingly refined and selective strategies for increased efficacy and longevity, targeting bromodomains with enhanced precision to induce gene silencing through novel mechanisms including selective BRD4 inhibitors, bromodomain specific molecules, covalent and allosteric BRD4 inhibitors, targeted protein degraders and combination treatments.
This report delivers a thorough analysis of the evolving landscape of BRD4 targeted therapies including scientific rationales, drug development approaches, clinical updates, novel technologies, competitive landscape and the potential commercial future. It provides insights for investors and pharmaceutical companies in identifying key market opportunities, novel technologies, competitive landscape and opportunities for investment, collaboration and portfolio development for the emerging BRD4 targeting therapy market.
Clinical Trials Insight Included In Report
The clinical development plays an important role in evaluating the future prospects of BRD4 targeted treatments. There is no approved treatment directed against BRD4 so far; however, a number of candidates have completed or are ongoing in clinical research for BRD4 targeted therapies in various hematological malignancies and solid tumors. The report analyzes the current pipeline of BRD4 targeted treatment candidates, as well as those in early and advanced stages of clinical research, that target BRD4 and BET inhibitors in diseases such as acute myeloid leukemia, myelofibrosis, lymphomas, prostate cancer, pediatric cancers, and solid tumors.
This report includes extensive research on current clinical trials and studies targeting BRD4, which involve a wide array of indications, patient populations, clinical phase, and treatments. The information provided involves an analysis of BRD4 monotherapy, as well as combination approach, focusing on the use of BRD4 targeted drugs in combination with epigenetic drugs, apoptosis inducers, kinase inhibitors, DNA repair treatment, and immunotherapy. Furthermore, information about the organizations carrying out the research, such as pharmaceutical companies, biopharmaceutical organizations, and academia, is included in this report, giving a clear picture to the readers regarding the sponsors of BRD4 targeted therapies.
Major Companies Active In R&D Of BRD4 Targeted Therapies
In terms of therapeutic landscape, BRD4 involves a wide range of pharmaceutical companies and biotech firms, as well as research organizations involved in the development of BRD4 targeting drugs in various therapeutic fields. The initial efforts of drug development were mainly represented by companies working on BET inhibitors, as evidenced by development of pelabresib, PLX2853, BMS-986158 and ABBV-075 programs, which contributed to clinical knowledge of BRD4 inhibition in hematology and oncology. These early programs laid the groundwork for the clinical relevance of BRD4 and paved the way for new developments in selective and next generation approaches.
The current competitive landscape consists of companies that develop novel BRD4 targeting strategies, including selective BRD4 inhibitors, degradation of BRD4 protein, and combination therapy. Some of these biotech firms include Halda Therapeutics, DeepCure, Model Medicines, and others. In addition, academic institutions provide the foundation of the competitive landscape through the discovery of novel mechanisms of regulation and treatment opportunities for BRD4. It should be noted that increasing number of industry participants, collaborations, and investments of pharmaceutical companies into drug development of BRD4 show commercial potential of this approach to drug development.
Technology Platforms, Collaborations & Agreements
Technological advancements have resulted in the exploration of non-traditional treatment methods that utilize platforms developed by the companies to modulate the targets in a more selective and sustainable manner. Innovative treatment modalities include protein degradation, such as PROTAC and molecular glues, AI enabled drug discovery, RNA silencing, and precision delivery of the compounds. For instance, the RIPTAC™ technology of Halda Therapeutics is an innovative platform targeting the disruption of essential cancerous proteins in tumor cells to develop the product called HLD-0915 for treating prostate cancer. These platforms seek to overcome the challenges of traditional BET inhibitors and develop next generation treatments based on BRD4.
Collaborations involving biotech companies, pharmaceuticals, and academic research institutions have continued to boost innovation in this sphere. Collaborations aimed at developing protein degradation, AI enabled drug discovery, biomarker identification, and precise delivery technologies broaden the range of potential uses for BRD4 based therapies. The report evaluates key technological developments, partnerships, licenses, and platform approaches that will shape the future of BRD4 targeting therapy development.
Report Indicating Future Direction Of BRD4 Targeted Therapies
Precision, new modes of action, and expanded applications represent likely themes for BRD4 targeting therapies in the future. Next generation inhibitors that would target either BRD4 or specific bromodomains may allow opening of additional therapeutic windows, whereas degradation technologies may offer greater ability to silence transcription programs regulated by BRD4. Combination technologies may also play a major role in the growth of BRD4 targeting therapies, which may allow complementing conventional anti-cancer drugs and overcoming resistance mechanisms.
In addition to oncology, a growing understanding of BRD4 biology may open up new horizons for BRD4 therapies in inflammatory diseases, cardiovascular disorders, infectious diseases, and other indications that feature abnormal transcription regulation. The convergence of biomarker driven patient selection, advanced drug delivery technologies, and novel therapeutic platforms will define the future direction of BRD4 research and development. The report offers a comprehensive assessment of these opportunities, providing perspectives on scientific advancement, commercial potential, and future positioning of therapies targeting BRD4.
- First BRD4 Targeted Approval Expected By 2030
- Emergence Of BRD4 As A Lead BET Target
- Comprehensive Analysis of Novel Therapeutic Strategies Targeting BRD4
- BRD4 Targeting Therapies Clinical Trials Insight: > 20 Therapies In Trials
- Global BRD4 Targeting Therapies Clinical Trials By Company, Indication & Phase
- Technology and Drug Development Platforms Driving Next Generation BRD4 Therapies
- Competitive Landscape
BRD4 targeted therapies is one of the most rapidly evolving, most exciting and promising sub field within both epigenetic drug development and precision oncology landscape. As the crucial master transcriptional regulator controlling tumor growth, proliferation, metastasis, immunity, resistance to treatment, the bromodomain containing protein 4 (BRD4) has become an incredibly exciting target in the treatment of multiple cancer types. Different from existing cancer drug targets modulating specific signaling pathways, BRD4 as a transcriptional hub plays a pivotal role to orchestrate tumor’s key oncogenic transcriptional program including MYC driven gene expression and super enhancer function.
The path to the development of BRD4 targeted therapies has evolved from first generation pan BET inhibitors to increasingly refined and selective strategies for increased efficacy and longevity, targeting bromodomains with enhanced precision to induce gene silencing through novel mechanisms including selective BRD4 inhibitors, bromodomain specific molecules, covalent and allosteric BRD4 inhibitors, targeted protein degraders and combination treatments.
This report delivers a thorough analysis of the evolving landscape of BRD4 targeted therapies including scientific rationales, drug development approaches, clinical updates, novel technologies, competitive landscape and the potential commercial future. It provides insights for investors and pharmaceutical companies in identifying key market opportunities, novel technologies, competitive landscape and opportunities for investment, collaboration and portfolio development for the emerging BRD4 targeting therapy market.
Clinical Trials Insight Included In Report
The clinical development plays an important role in evaluating the future prospects of BRD4 targeted treatments. There is no approved treatment directed against BRD4 so far; however, a number of candidates have completed or are ongoing in clinical research for BRD4 targeted therapies in various hematological malignancies and solid tumors. The report analyzes the current pipeline of BRD4 targeted treatment candidates, as well as those in early and advanced stages of clinical research, that target BRD4 and BET inhibitors in diseases such as acute myeloid leukemia, myelofibrosis, lymphomas, prostate cancer, pediatric cancers, and solid tumors.
This report includes extensive research on current clinical trials and studies targeting BRD4, which involve a wide array of indications, patient populations, clinical phase, and treatments. The information provided involves an analysis of BRD4 monotherapy, as well as combination approach, focusing on the use of BRD4 targeted drugs in combination with epigenetic drugs, apoptosis inducers, kinase inhibitors, DNA repair treatment, and immunotherapy. Furthermore, information about the organizations carrying out the research, such as pharmaceutical companies, biopharmaceutical organizations, and academia, is included in this report, giving a clear picture to the readers regarding the sponsors of BRD4 targeted therapies.
Major Companies Active In R&D Of BRD4 Targeted Therapies
In terms of therapeutic landscape, BRD4 involves a wide range of pharmaceutical companies and biotech firms, as well as research organizations involved in the development of BRD4 targeting drugs in various therapeutic fields. The initial efforts of drug development were mainly represented by companies working on BET inhibitors, as evidenced by development of pelabresib, PLX2853, BMS-986158 and ABBV-075 programs, which contributed to clinical knowledge of BRD4 inhibition in hematology and oncology. These early programs laid the groundwork for the clinical relevance of BRD4 and paved the way for new developments in selective and next generation approaches.
The current competitive landscape consists of companies that develop novel BRD4 targeting strategies, including selective BRD4 inhibitors, degradation of BRD4 protein, and combination therapy. Some of these biotech firms include Halda Therapeutics, DeepCure, Model Medicines, and others. In addition, academic institutions provide the foundation of the competitive landscape through the discovery of novel mechanisms of regulation and treatment opportunities for BRD4. It should be noted that increasing number of industry participants, collaborations, and investments of pharmaceutical companies into drug development of BRD4 show commercial potential of this approach to drug development.
Technology Platforms, Collaborations & Agreements
Technological advancements have resulted in the exploration of non-traditional treatment methods that utilize platforms developed by the companies to modulate the targets in a more selective and sustainable manner. Innovative treatment modalities include protein degradation, such as PROTAC and molecular glues, AI enabled drug discovery, RNA silencing, and precision delivery of the compounds. For instance, the RIPTAC™ technology of Halda Therapeutics is an innovative platform targeting the disruption of essential cancerous proteins in tumor cells to develop the product called HLD-0915 for treating prostate cancer. These platforms seek to overcome the challenges of traditional BET inhibitors and develop next generation treatments based on BRD4.
Collaborations involving biotech companies, pharmaceuticals, and academic research institutions have continued to boost innovation in this sphere. Collaborations aimed at developing protein degradation, AI enabled drug discovery, biomarker identification, and precise delivery technologies broaden the range of potential uses for BRD4 based therapies. The report evaluates key technological developments, partnerships, licenses, and platform approaches that will shape the future of BRD4 targeting therapy development.
Report Indicating Future Direction Of BRD4 Targeted Therapies
Precision, new modes of action, and expanded applications represent likely themes for BRD4 targeting therapies in the future. Next generation inhibitors that would target either BRD4 or specific bromodomains may allow opening of additional therapeutic windows, whereas degradation technologies may offer greater ability to silence transcription programs regulated by BRD4. Combination technologies may also play a major role in the growth of BRD4 targeting therapies, which may allow complementing conventional anti-cancer drugs and overcoming resistance mechanisms.
In addition to oncology, a growing understanding of BRD4 biology may open up new horizons for BRD4 therapies in inflammatory diseases, cardiovascular disorders, infectious diseases, and other indications that feature abnormal transcription regulation. The convergence of biomarker driven patient selection, advanced drug delivery technologies, and novel therapeutic platforms will define the future direction of BRD4 research and development. The report offers a comprehensive assessment of these opportunities, providing perspectives on scientific advancement, commercial potential, and future positioning of therapies targeting BRD4.
1. RESEARCH METHODOLOGY
2. INTRODUCTION TO BET FAMILY & BRD4 TARGETING
2.1 Overview Of Epigenetic Drug Targets
2.2 Biology & Function Of The BET Protein Family
2.3 BET Proteins As Therapeutic Targets
2.4 Emergence Of BRD4 As A Lead BET Target
2.5 Historical Development Of BRD4-Targeted Therapies
3. BIOLOGICAL RATIONALE FOR TARGETING BRD4
3.1 Structure & Domain Organization Of BRD4
3.2 Biological Functions Of BRD4
3.3 Role Of BRD4 In Gene Regulation
3.4 Role Of BRD4 In Cancer Hallmarks
4. THERAPEUTIC APPROACHES TARGETING BRD4
4.1 Small-Molecule BRD4/BET Inhibitors
4.1.1 First-Generation BET Inhibitors
4.1.2 Next-Generation & Selective BET Inhibitors
4.2 BRD4 Protein Degradation Approaches
4.2.1 PROTAC-Based BRD4 Degraders
4.2.2 Molecular Glue Degraders
4.3 Gene Silencing Strategies
4.3.1 RNA-Based Gene Silencing
4.3.2 CRISPR-Based BRD4 Targeting
4.4 Drug Repurposing Strategies
4.5 Emerging BRD4-Targeting Strategies
4.5.1 Covalent & Allosteric BRD4 Inhibitors
4.5.2 Dual-Target BRD4 Therapeutics
5. DISEASE BIOLOGY & THERAPEUTIC RATIONALE
5.1 BRD4 in Cancer
5.1.1 Hematological Malignancies
5.1.2 Solid Tumors
5.2 Non-Oncology Opportunities
5.2.1 Autoimmune & Inflammatory Diseases
5.2.2 Microbial Infections
5.2.3 Cardiovascular Diseases
6. BRD4 TARGETED THERAPIES COMBINATION THERAPEUTIC APPROACHES
6.1 BRD4 Targeted Therapies With Epigenetic Drugs
6.2 BRD4 Targeted Therapies With Tyrosine Kinase Inhibitors
6.3 BRD4 Targeted Therapies With BCL-2 Inhibitors
6.4 BRD4 Targeted Therapies With Photodynamic Therapy
7. GLOBAL BRD4 TARGETED THERAPIES CLINICAL TRIALS OVERVIEW
7.1 By Phase
7.2 By Country
7.3 By Company
7.4 By Indication
7.5 By Priority Status
8. GLOBAL BRD4 TARGETED THERAPIES CLINICAL TRIALS BY COMPANY, INDICATION & PHASE
8.1 Research
8.2 Preclinical
8.3 Phase-I
8.4 Phase-I/II
8.5 Phase-II
8.6 Phase-III
9. BRD4 TARGETED THERAPIES DEVELOPMENT PLATFORMS
10. GLOBAL BRD4 TARGETED THERAPIES MARKET TREND & DEVELOPMENTS
10.1 Current Market Outline
10.2 Future Development Directions
11. GLOBAL BRD4 TARGETED THERAPIES MARKET DYNAMICS
11.1 Market Drivers & Opportunities
11.2 Market Challenges & Restraints
12. COMPETITIVE LANDSCAPE
12.1 DeepCure
12.2 Epigenetix
12.3 Inhalis Therapeutics
12.4 Kainos Medicines
12.5 Mitsubishi Tanabe Pharma Corporation
12.6 Model Medicines
12.7 Opna Bio
12.8 Plexium
12.9 Prazer Therapeutics
12.10 Ranok Therapeutics
2. INTRODUCTION TO BET FAMILY & BRD4 TARGETING
2.1 Overview Of Epigenetic Drug Targets
2.2 Biology & Function Of The BET Protein Family
2.3 BET Proteins As Therapeutic Targets
2.4 Emergence Of BRD4 As A Lead BET Target
2.5 Historical Development Of BRD4-Targeted Therapies
3. BIOLOGICAL RATIONALE FOR TARGETING BRD4
3.1 Structure & Domain Organization Of BRD4
3.2 Biological Functions Of BRD4
3.3 Role Of BRD4 In Gene Regulation
3.4 Role Of BRD4 In Cancer Hallmarks
4. THERAPEUTIC APPROACHES TARGETING BRD4
4.1 Small-Molecule BRD4/BET Inhibitors
4.1.1 First-Generation BET Inhibitors
4.1.2 Next-Generation & Selective BET Inhibitors
4.2 BRD4 Protein Degradation Approaches
4.2.1 PROTAC-Based BRD4 Degraders
4.2.2 Molecular Glue Degraders
4.3 Gene Silencing Strategies
4.3.1 RNA-Based Gene Silencing
4.3.2 CRISPR-Based BRD4 Targeting
4.4 Drug Repurposing Strategies
4.5 Emerging BRD4-Targeting Strategies
4.5.1 Covalent & Allosteric BRD4 Inhibitors
4.5.2 Dual-Target BRD4 Therapeutics
5. DISEASE BIOLOGY & THERAPEUTIC RATIONALE
5.1 BRD4 in Cancer
5.1.1 Hematological Malignancies
5.1.2 Solid Tumors
5.2 Non-Oncology Opportunities
5.2.1 Autoimmune & Inflammatory Diseases
5.2.2 Microbial Infections
5.2.3 Cardiovascular Diseases
6. BRD4 TARGETED THERAPIES COMBINATION THERAPEUTIC APPROACHES
6.1 BRD4 Targeted Therapies With Epigenetic Drugs
6.2 BRD4 Targeted Therapies With Tyrosine Kinase Inhibitors
6.3 BRD4 Targeted Therapies With BCL-2 Inhibitors
6.4 BRD4 Targeted Therapies With Photodynamic Therapy
7. GLOBAL BRD4 TARGETED THERAPIES CLINICAL TRIALS OVERVIEW
7.1 By Phase
7.2 By Country
7.3 By Company
7.4 By Indication
7.5 By Priority Status
8. GLOBAL BRD4 TARGETED THERAPIES CLINICAL TRIALS BY COMPANY, INDICATION & PHASE
8.1 Research
8.2 Preclinical
8.3 Phase-I
8.4 Phase-I/II
8.5 Phase-II
8.6 Phase-III
9. BRD4 TARGETED THERAPIES DEVELOPMENT PLATFORMS
10. GLOBAL BRD4 TARGETED THERAPIES MARKET TREND & DEVELOPMENTS
10.1 Current Market Outline
10.2 Future Development Directions
11. GLOBAL BRD4 TARGETED THERAPIES MARKET DYNAMICS
11.1 Market Drivers & Opportunities
11.2 Market Challenges & Restraints
12. COMPETITIVE LANDSCAPE
12.1 DeepCure
12.2 Epigenetix
12.3 Inhalis Therapeutics
12.4 Kainos Medicines
12.5 Mitsubishi Tanabe Pharma Corporation
12.6 Model Medicines
12.7 Opna Bio
12.8 Plexium
12.9 Prazer Therapeutics
12.10 Ranok Therapeutics
LIST OF TABLES
Table 2-1: Classification Of Epigenetic Regulators
Table 2-2: BET Family Members & Tissue Distribution
Table 2-3: BET Proteins As Drug Targets - Advantages & Challenges
Table 2-4: Major Discoveries That Established BRD4 As The Lead BET Target
Table 3-1: BRD4-Mediated Gene Regulation Mechanisms
Table 3-2: Effect Of BRD4 Inhibition On Cancer Hallmarks
Table 4-1: First-Generation BET Inhibitors - Advantages & Limitations
Table 4-2: Comparison Of BET Inhibition Strategies
Table 4-3: PROTAC vs Molecular Glue: Structural & Pharmacological Comparison
Table 4-4: siRNA vs shRNA vs ASO vs miRNA: Functional Comparison
Table 4-5: BRD4 Drug Repurposing - Advantages & Limitations
Table 4-6: Dual BRD4 Therapeutics - Advantages & Challenges
Table 5-1: BRD4-Targeted Antimicrobial Therapy - Advantages & Challenges
Table 6-1: Representative BRD4–Photodynamic Therapy Strategies
Table 11-1: Global BRD4 Targeting Therapies Market –Challenges & Potential Solutions
Table 2-1: Classification Of Epigenetic Regulators
Table 2-2: BET Family Members & Tissue Distribution
Table 2-3: BET Proteins As Drug Targets - Advantages & Challenges
Table 2-4: Major Discoveries That Established BRD4 As The Lead BET Target
Table 3-1: BRD4-Mediated Gene Regulation Mechanisms
Table 3-2: Effect Of BRD4 Inhibition On Cancer Hallmarks
Table 4-1: First-Generation BET Inhibitors - Advantages & Limitations
Table 4-2: Comparison Of BET Inhibition Strategies
Table 4-3: PROTAC vs Molecular Glue: Structural & Pharmacological Comparison
Table 4-4: siRNA vs shRNA vs ASO vs miRNA: Functional Comparison
Table 4-5: BRD4 Drug Repurposing - Advantages & Limitations
Table 4-6: Dual BRD4 Therapeutics - Advantages & Challenges
Table 5-1: BRD4-Targeted Antimicrobial Therapy - Advantages & Challenges
Table 6-1: Representative BRD4–Photodynamic Therapy Strategies
Table 11-1: Global BRD4 Targeting Therapies Market –Challenges & Potential Solutions
LIST OF FIGURES
Figure 2-1: Overview Of Epigenetic Regulation & Therapeutic Target Classes
Figure 2-2: Overview Of Epigenetic Machinery
Figure 2-3: Structural Organization Of BET Proteins
Figure 2-4: BET Protein-Mediated Recognition Of Histone Acetylation - Mechanism
Figure 2-5: BET-Dependent Transcriptional Addiction In Cancer
Figure 2-6: Cancers Associated With BRD4 Dysregulation
Figure 2-7: BRD4 Therapeutic Strategies - Evolution
Figure 2-8: BRD4-Targeted Therapy Development - Historical Timeline
Figure 3-1: BRD4 Protein - Functional Architecture
Figure 3-2: BRD4 - Integrator Of Multiple Cellular Pathways
Figure 3-3: BRD4 - Major Biological Functions
Figure 3-4: BRD4 Coordinates Multiple Levels Of Gene Regulation
Figure 3-5: BRD4 In The Hallmarks Of Cancer
Figure 4-1: First-Generation BET Inhibitors - Mechanism & Limitations
Figure 4-2: Representative First-Generation BET Inhibitors
Figure 4-3: Evolution Towards Selective BET Inhibitors
Figure 4-4: BRD4 Degradation Via PROTAC
Figure 4-5: BRD4 PROTAC Degraders - Advantages
Figure 4-6: Molecular Glue-Mediated BRD4 Degradation - Mechanism
Figure 4-7: Molecular Glue Degraders For BRD4 Therapy - Advantages
Figure 4-8: CRISPRi vs CRISPRa: Bidirectional Control Of BRD4 Expression
Figure 4-9: CRISPR Technologies For BRD4 Research - Evolution
Figure 4-10: Challenges Limiting Clinical Translation o&f BRD4 CRISPR Therapy
Figure 4-11: Drug Repurposing Strategies For BRD4 Targeting - Overview
Figure 4-12: Next-Generation BRD4-Selective Inhibitors
Figure 4-13: Covalent BRD4 Inhibition - Mechanism
Figure 4-14: Canonical vs Non-Canonical BRD4 Binding
Figure 4-15: Allosteric BRD4 Inhibition - Mechanism
Figure 4-16: Next-Generation BRD4 Inhibitor Development - Challenges
Figure 4-17: Dual-Target BRD4 Therapeutics - Concept
Figure 5-1: CHAMP-1 Phase 1/2 (NCT05487170) Study – Initiation & Completion Year
Figure 5-2: CA011-023 Phase 1/2 (NCT04817007) Study – Initiation & Completion Year
Figure 5-3: NCI-2022-04100 Phase 1 (NCT05372640) Study – Initiation & Completion Year
Figure 5-4: NCI-2020-04495 Phase 1 (NCT04471974) Study – Initiation & Completion Year
Figure 5-5: NCI-2023-03408 Phase 1 (NCT05950464) Study – Initiation & Completion Year
Figure 5-6: HLD-0915-ONC-101 Phase 1/2 (NCT06800313) Study – Initiation & Completion Year
Figure 5-7: Autoimmune & Inflammatory Diseases - Therapeutic Applications Of BRD4 Inhibition
Figure 5-8: BRD4 As A Host-Directed Therapeutic Target In Microbial Infections
Figure 5-9: BRD4 As A Central Regulator Of Cardiovascular Diseases
Figure 6-1: Rationale For Combining BRD4 Inhibitors With Epigenetic Therapies
Figure 6-2: BRD4-TKIs Combination Therapy - Rationale
Figure 6-3: BRD4-BCL-2 Combination Therapy - Rationale
Figure 6-4: BRD4 Inhibition & Photodynamic Therapy Combination - Biological Effects
Figure 7-1: Global – Number Of BRD4 Targeted Therapies In Clinical Trials By Phase, 2026
Figure 7 -2: Global – Number Of BRD4 Targeted Therapies Clinical Trials By Country, 2026
Figure 7-3: Global – Number Of BRD4 Targeted Therapies Clinical Trials By Company, 2026
Figure 7-4: Global – Number Of BRD4 Targeted Therapies Clinical Trials By Indication, 2026
Figure 7-5: Global – Number Of BRD4 Targeted Therapies Clinical Trials By Priority Status, 2026
Figure 9-1: Vyne Therapeutics - BET Inhibitor Platform
Figure 10-1: BRD4-Targeted Therapeutics - Future Opportunities
Figure 11-1: Global BRD4 Targeting Therapies Market – Favorable Parameters
Figure 2-1: Overview Of Epigenetic Regulation & Therapeutic Target Classes
Figure 2-2: Overview Of Epigenetic Machinery
Figure 2-3: Structural Organization Of BET Proteins
Figure 2-4: BET Protein-Mediated Recognition Of Histone Acetylation - Mechanism
Figure 2-5: BET-Dependent Transcriptional Addiction In Cancer
Figure 2-6: Cancers Associated With BRD4 Dysregulation
Figure 2-7: BRD4 Therapeutic Strategies - Evolution
Figure 2-8: BRD4-Targeted Therapy Development - Historical Timeline
Figure 3-1: BRD4 Protein - Functional Architecture
Figure 3-2: BRD4 - Integrator Of Multiple Cellular Pathways
Figure 3-3: BRD4 - Major Biological Functions
Figure 3-4: BRD4 Coordinates Multiple Levels Of Gene Regulation
Figure 3-5: BRD4 In The Hallmarks Of Cancer
Figure 4-1: First-Generation BET Inhibitors - Mechanism & Limitations
Figure 4-2: Representative First-Generation BET Inhibitors
Figure 4-3: Evolution Towards Selective BET Inhibitors
Figure 4-4: BRD4 Degradation Via PROTAC
Figure 4-5: BRD4 PROTAC Degraders - Advantages
Figure 4-6: Molecular Glue-Mediated BRD4 Degradation - Mechanism
Figure 4-7: Molecular Glue Degraders For BRD4 Therapy - Advantages
Figure 4-8: CRISPRi vs CRISPRa: Bidirectional Control Of BRD4 Expression
Figure 4-9: CRISPR Technologies For BRD4 Research - Evolution
Figure 4-10: Challenges Limiting Clinical Translation o&f BRD4 CRISPR Therapy
Figure 4-11: Drug Repurposing Strategies For BRD4 Targeting - Overview
Figure 4-12: Next-Generation BRD4-Selective Inhibitors
Figure 4-13: Covalent BRD4 Inhibition - Mechanism
Figure 4-14: Canonical vs Non-Canonical BRD4 Binding
Figure 4-15: Allosteric BRD4 Inhibition - Mechanism
Figure 4-16: Next-Generation BRD4 Inhibitor Development - Challenges
Figure 4-17: Dual-Target BRD4 Therapeutics - Concept
Figure 5-1: CHAMP-1 Phase 1/2 (NCT05487170) Study – Initiation & Completion Year
Figure 5-2: CA011-023 Phase 1/2 (NCT04817007) Study – Initiation & Completion Year
Figure 5-3: NCI-2022-04100 Phase 1 (NCT05372640) Study – Initiation & Completion Year
Figure 5-4: NCI-2020-04495 Phase 1 (NCT04471974) Study – Initiation & Completion Year
Figure 5-5: NCI-2023-03408 Phase 1 (NCT05950464) Study – Initiation & Completion Year
Figure 5-6: HLD-0915-ONC-101 Phase 1/2 (NCT06800313) Study – Initiation & Completion Year
Figure 5-7: Autoimmune & Inflammatory Diseases - Therapeutic Applications Of BRD4 Inhibition
Figure 5-8: BRD4 As A Host-Directed Therapeutic Target In Microbial Infections
Figure 5-9: BRD4 As A Central Regulator Of Cardiovascular Diseases
Figure 6-1: Rationale For Combining BRD4 Inhibitors With Epigenetic Therapies
Figure 6-2: BRD4-TKIs Combination Therapy - Rationale
Figure 6-3: BRD4-BCL-2 Combination Therapy - Rationale
Figure 6-4: BRD4 Inhibition & Photodynamic Therapy Combination - Biological Effects
Figure 7-1: Global – Number Of BRD4 Targeted Therapies In Clinical Trials By Phase, 2026
Figure 7 -2: Global – Number Of BRD4 Targeted Therapies Clinical Trials By Country, 2026
Figure 7-3: Global – Number Of BRD4 Targeted Therapies Clinical Trials By Company, 2026
Figure 7-4: Global – Number Of BRD4 Targeted Therapies Clinical Trials By Indication, 2026
Figure 7-5: Global – Number Of BRD4 Targeted Therapies Clinical Trials By Priority Status, 2026
Figure 9-1: Vyne Therapeutics - BET Inhibitor Platform
Figure 10-1: BRD4-Targeted Therapeutics - Future Opportunities
Figure 11-1: Global BRD4 Targeting Therapies Market – Favorable Parameters
